Mackay Shields LLC Nektar Therapeutics Transaction History

Mackay Shields LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 01, 2019	SELL	$16.91 - $36.27 $442,213 - $948,496	-26,151 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$31.0 - $36.3 $29,636 - $34,702	956 Added 3.79%	26,151 $931,000
Q1 2019 May 13, 2019	SELL	$31.58 - $46.35 $36,064 - $52,931	-1,142 Reduced 4.34%	25,195 $847,000
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $188,361 - $350,663	-6,190 Reduced 19.03%	26,337 $866,000
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $299,713 - $441,828	6,451 Added 24.74%	32,527 $1.98 Million
Q2 2018 Aug 06, 2018	SELL	$46.25 - $104.45 $1.66 Million - $3.75 Million	-35,942 Reduced 57.95%	26,076 $1.27 Million
Q1 2018 May 03, 2018	BUY	$57.4 - $108.44 $3.56 Million - $6.73 Million	62,018 New	62,018 $6.59 Million

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

Stay updated on Mackay Shields LLC with notifications on news.